Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + cytarabine + granulocyte colony-stimulating factor
- Development stage
- Preclinical
- Lead developer
- Takeda
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
This is a combination chemotherapy regimen consisting of cyclophosphamide (an alkylating agent), cytarabine (a nucleoside analog antimetabolite), and granulocyte colony-stimulating factor (G-CSF, a hematopoietic growth factor). Cyclophosphamide acts by cross-linking DNA strands and inhibiting DNA replication. Cytarabine inhibits DNA synthesis by acting as an antimetabolite of cytidine. G-CSF stimulates the proliferation and differentiation of neutrophil precursors to reduce the duration and severity of chemotherapy-induced neutropenia. This combination is used in hematologic malignancies such as acute lymphoblastic leukemia (ALL) and for stem cell mobilization prior to autologous stem cell transplantation in multiple myeloma[4][6][8]. The addition of G-CSF helps mitigate neutropenia-related complications during intensive chemotherapy.
- Other names
- cyclophosphamidecytarabineG-CSF
02
Targets
DNA polymerase familyCSF3R (Granulocyte colony-stimulating factor receptor)DNA
Beyond the preview
Go deeper on cyclophosphamide + cytarabine + granulocyte colony-stimulating factor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + cytarabine + granulocyte colony-stimulating factor.